Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Yesterday, June 11, 2015, 92 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $332.85 to $17,302,509.00.
Highlighted Stocks Traded by Insiders:
Micron Technology (MU) - FREE Research Report Deboer Scott J, who is Vice President, R&D at Micron Technology, sold 39,087 shares at $25.01 on June 11, 2015. Following this transaction, the Vice President, R&D owned 148,141 shares meaning that the stake was reduced by 20.88% with the 39,087-share transaction.
The shares most recently traded at $25.22, up $0.21, or 0.85% since the insider transaction. Historical insider transactions for Micron Technology go as follows:
- 4-Week # shares sold: 4,000
- 12-Week # shares sold: 55,250
- 24-Week # shares sold: 108,500
The average volume for Micron Technology has been 22.5 million shares per day over the past 30 days. Micron Technology has a market cap of $27.2 billion and is part of the technology sector and electronics industry. Shares are down 28.53% year-to-date as of the close of trading on Thursday.
Micron Technology, Inc., together with its subsidiaries, provides semiconductor solutions worldwide. The company manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems. The company has a P/E ratio of 7.8. Currently, there are 17 analysts who rate Micron Technology a buy, 1 analyst rates it a sell, and 3 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on MU - FREE TheStreet Quant Ratings rates Micron Technology as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full
Micron Technology Ratings Report from
TheStreet Quant Ratings now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Peapack Gladstone Financial (PGC) - FREE Research Report Waser Eric H., who is EVP, Head of Comm Banking at Peapack Gladstone Financial, bought 1,000 shares at $20.50 on June 11, 2015. Following this transaction, the EVP, Head of Comm Banking owned 11,666 shares meaning that the stake was boosted by 9.38% with the 1,000-share transaction.
The shares most recently traded at $20.56, up $0.06, or 0.29% since the insider transaction. Historical insider transactions for Peapack Gladstone Financial go as follows:
- 4-Week # shares bought: 1,000
- 12-Week # shares bought: 1,000
- 12-Week # shares sold: 6,000
- 24-Week # shares bought: 1,000
- 24-Week # shares sold: 6,000
The average volume for Peapack Gladstone Financial has been 32,500 shares per day over the past 30 days. Peapack Gladstone Financial has a market cap of $319.0 million and is part of the financial sector and banking industry. Shares are up 10.99% year-to-date as of the close of trading on Thursday.
Peapack-Gladstone Financial Corporation operates as the bank holding company for Peapack-Gladstone Bank that provides private banking and wealth management services primarily to businesses, non-profits, and consumers in New Jersey. The stock currently has a dividend yield of 0.97%. The company has a P/E ratio of 16.0.
Exclusive Offer: Get the latest Stock Analysis on PGC - FREE TheStreet Quant Ratings rates Peapack Gladstone Financial as a
buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, solid stock price performance and reasonable valuation levels. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full
Peapack Gladstone Financial Ratings Report from
TheStreet Quant Ratings now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
National Healthcare (NHC) - FREE Research Report Lassiter David L, who is Sr. V.P., Corporate Affairs at National Healthcare, sold 2,000 shares at $63.50 on June 11, 2015. Following this transaction, the Sr. V.P., Corporate Affairs owned 25,381 shares meaning that the stake was reduced by 7.3% with the 2,000-share transaction.
The shares most recently traded at $63.75, up $0.25, or 0.39% since the insider transaction. Historical insider transactions for National Healthcare go as follows:
- 4-Week # shares sold: 3,310
- 12-Week # shares sold: 3,310
- 24-Week # shares sold: 7,310
The average volume for National Healthcare has been 13,700 shares per day over the past 30 days. National Healthcare has a market cap of $903.9 million and is part of the health care sector and health services industry. Shares are up 1.16% year-to-date as of the close of trading on Thursday.
National HealthCare Corporation operates, manages, or provides services to skilled nursing facilities and associated assisted living centers, retirement centers, and home health care programs. The stock currently has a dividend yield of 2.52%. The company has a P/E ratio of 20.3. Currently, there are no analysts who rate National Healthcare a buy, no analysts rate it a sell, and none rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on NHC - FREE TheStreet Quant Ratings rates National Healthcare as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full
National Healthcare Ratings Report from
TheStreet Quant Ratings now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
